scholarly article | Q13442814 |
P356 | DOI | 10.1177/00912709922007606 |
P698 | PubMed publication ID | 11563410 |
P2093 | author name string | McLeod JF | |
Dunning BE | |||
Karara AH | |||
P2860 | cites work | Interactions affecting drug absorption | Q40191959 |
Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166). | Q41140104 | ||
Effect of food on the bioavailability of SDZ DJN 608, an oral hypoglycemic agent, from a tablet and a liquid-filled capsule in the dog. | Q51582537 | ||
Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals. | Q51611366 | ||
N-(cyclohexylcarbonyl)-D-phenylalanines and related compounds. A new class of oral hypoglycemic agents. 2 | Q69640963 | ||
Effects of N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166) on insulin and glucagon secretion in isolated perfused rat pancreas | Q72408696 | ||
Solubilizing properties of bile salt solutions. II. Effect of inorganic electrolyte, lipids, and a mixed bile salt system on solubilization of glutethimide, griseofulvin, and hexestrol | Q72798646 | ||
P433 | issue | 2 | |
P921 | main subject | bioavailability | Q461809 |
pharmacodynamics | Q725307 | ||
P304 | page(s) | 172-179 | |
P577 | publication date | 1999-02-01 | |
P1433 | published in | The Journal of Clinical Pharmacology | Q7743562 |
P1476 | title | The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects. | |
P478 | volume | 39 |
Q44744484 | A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes |
Q36596836 | A review of nateglinide in the management of patients with type 2 diabetes. |
Q38780360 | Antioxidant properties of drugs used in Type 2 diabetes management: could they contribute to, confound or conceal effects of antioxidant therapy? |
Q34549886 | Approaches to preventing mealtime hyperglycaemic excursions |
Q34544816 | Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent |
Q38167147 | Complications of diabetes therapy. |
Q50192729 | Development and validation of analytical method for the estimation of nateglinide in rabbit plasma |
Q36718446 | Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide |
Q44579048 | Effects of nateglinide on the secretion of glycated insulin and glucose tolerance in type 2 diabetes |
Q44317938 | Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure |
Q37184422 | Influence of food intake on the bioavailability and efficacy of oral calcitonin |
Q34453173 | Insulinotropic meglitinide analogues |
Q35557405 | Lessons learned from the clinical development of oral peptides |
Q37775799 | Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials |
Q30630393 | Meglitinide analogues in the treatment of type 2 diabetes mellitus |
Q34059381 | Nateglinide |
Q34449447 | Nateglinide therapy for type 2 diabetes mellitus |
Q34390267 | Nateglinide: a new rapid-acting insulinotropic agent |
Q44237132 | No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers |
Q33368276 | Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of Salmon Calcitonin |
Q42695854 | Pharmacokinetics of nateglinide in renally impaired diabetic patients |
Q33975364 | Quo vadis nateglinide? Ten-year perspective |
Q44341435 | Rapid and simple method for the analysis of nateglinide in human plasma using HPLC analysis with UV detection |
Q40585698 | Separation and quantification of eight antidiabetic drugs on a high-performance liquid chromatography: its application to human plasma assay |
Q44513024 | The effect of nateglinide taken with food on gastric emptying rates in healthy subjects |